Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 1.10 -0.03 (-2.91%)
As of 11:58 AM Eastern
Compare

CLBX vs. HVO, HEMO, COIL, C4XD, and DDDD

Should you buy Cellbxhealth stock or one of its competitors? Cellbxhealth's main competitors and comparable companies include hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to hVIVO?

Cellbxhealth (LON:CLBX) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 12.7% of hVIVO shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 134.38%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Cellbxhealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellbxhealth
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Cellbxhealth has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Cellbxhealth's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
hVIVO -12.48%-14.65%11.97%

hVIVO has higher revenue and earnings than Cellbxhealth. hVIVO is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M10.85N/A-£3.49N/A
hVIVO£46.77M0.94£17.84M-£0.87N/A

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
hVIVO Neutral

Summary

hVIVO beats Cellbxhealth on 8 of the 12 factors compared between the two stocks.

How does Cellbxhealth compare to Hemogenyx Pharmaceuticals?

Cellbxhealth (LON:CLBX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cellbxhealth has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M10.85N/A-£3.49N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Cellbxhealth's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Cellbxhealth beats Hemogenyx Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Cellbxhealth Neutral

Cellbxhealth has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Cellbxhealth£1.15M10.85N/A-£3.49N/A

1.8% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cellbxhealth has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Cellbxhealth's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Cellbxhealth N/A N/A N/A

Summary

Cellbxhealth beats Roquefort Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Cellbxhealth compare to C4X Discovery?

Cellbxhealth (LON:CLBX) and C4X Discovery (LON:C4XD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 52.1% of C4X Discovery shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 27.1% of C4X Discovery shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

C4X Discovery has a net margin of 42.81% compared to Cellbxhealth's net margin of 0.00%. C4X Discovery's return on equity of 55.38% beat Cellbxhealth's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
C4X Discovery 42.81%55.38%28.04%

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
C4X Discovery Neutral

C4X Discovery has higher revenue and earnings than Cellbxhealth. Cellbxhealth is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M10.85N/A-£3.49N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

Summary

C4X Discovery beats Cellbxhealth on 8 of the 8 factors compared between the two stocks.

How does Cellbxhealth compare to 4D pharma?

Cellbxhealth (LON:CLBX) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 26.8% of 4D pharma shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 12.2% of 4D pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
4D pharma Neutral

Cellbxhealth's return on equity of 0.00% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
4D pharma N/A -89.48%-42.64%

Cellbxhealth has higher revenue and earnings than 4D pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M10.85N/A-£3.49N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

Summary

Cellbxhealth beats 4D pharma on 5 of the 7 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£12.50M£3.88B£7.20B£2.87B
Dividend YieldN/A3.66%2.57%6.25%
P/E Ratio-0.3214.40273.84367.03
Price / Sales10.851,432.88638.3289,972.82
Price / CashN/A43.6428.4227.89
Price / BookN/A15.2610.436.30
Net IncomeN/A-£22.78M£3.49B£5.89B
7 Day Performance-0.54%-2.03%-2.11%-1.13%
1 Month Performance-18.22%2.10%0.64%-0.61%
1 Year PerformanceN/A42.58%24.61%19.59%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 1.10
-2.9%		N/AN/A£12.50M£1.15MN/AN/A
HVO
hVIVO
N/AGBX 7.20
+4.3%		GBX 15
+108.3%		-32.0%£49.57M£46.77MN/AN/A
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 515
-1.0%		N/A-56.7%£35.02MN/AN/A14
COIL
Roquefort Therapeutics
N/AGBX 8.13
+0.3%		N/A-58.5%£34.68MN/AN/A9
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
New Form of AI Could Ignite the ‘Great Wealth Rotation’
Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...
Chaikin Analytics | Sponsoredtc pixel
Elon Musk Predicts This Will be the Next Wave of AI
Nvidia CEO Jensen Huang says the Accelerated AI inflection has arrived. Elon Musk has predicted that 99 percen...
Brownstone Research | Sponsoredtc pixel